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Abstract
Background: The identification of the vitamin D receptor in the endocrine pancreas suggests a
role for vitamin D in insulin secretion. There is also some limited evidence that vitamin D influences
insulin resistance, and thus the early stages of the development of type 2 diabetes.
Methods:  Eighty-four women of South Asian origin, living in Auckland, New Zealand, were
randomised to receive either a supplement (4000IU 25(OH)D3 per day) or a placebo for 6 months.
At baseline, all participants were vitamin D deficient (serum 25(OH)D3 <50 nmol/L), insulin
resistant (HOMA-IR > 1.93) and/or hyperinsulinaemic, hyperglycemic or had clinical signs of
dislipidaemia. Changes in HOMA-IR, lipids, parathyroid hormone, calcium and bone markers were
monitored at 3 months and 6 months.
Discussion: This randomised, controlled trial will be the first to investigate the effect of vitamin
D supplementation on insulin resistance in non-diabetic subjects. It will subsequently contribute to
the growing body of evidence about the role of vitamin D in metabolic syndrome.Registered
clinical.
Trial registration: Registered clinical trial – Registration No. ACTRN12607000642482
Background
Hypovitaminosis D is becoming recognised as a world-
wide problem, and exists even in countries such as New
Zealand and Australia which enjoy plentiful sunshine and
latitudes sufficiently moderate to allow some endogenous
synthesis throughout the year [1-5]. Once thought to
impact only on bone health, there is now evidence to
implicate vitamin D deficiency in a plethora of adverse
health conditions such as cancer and auto-immune dis-
eases. There is mounting interest in the role of vitamin D
in the constellation of metabolic abnormalities grouped
under the term "metabolic syndrome", including hyper-
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tension, dyslipidaemia, abdominal obesity, glucose intol-
erance and type 2 diabetes.
Low serum vitamin D has been shown to correlate with
impaired glucose tolerance [1,6-8], whilst administration
of supplemental vitamin D to subjects with elevated
blood glucose levels has resulted in an improvement in
insulin secretion [9,10]. Similar improvements have been
observed in vitamin D-deficient subjects following sup-
plementation [6,11].
The role, if any, that vitamin D deficiency plays in insulin
resistance has had little investigation. Whilst a correlation
between hypovitaminosis D and insulin resistance has
been identified in pregnant women [12] and obese ado-
lescents [13] randomised, controlled trials with vitamin D
supplementation are sparse, especially in non-diabetic,
insulin resistant, vitamin D deficient subjects. Borissova et
al [10] measured a 29% (but not significant) decrease in
HOMA-IR following supplementation of 1332IU
25(OH)D3/day for one month in a group of 10 diabetic
women, 70% of whom were vitamin D deficient (<50
nmol/L). Pittas et.al. [14] saw a significantly lower
increase in HOMA-IR in vitamin D/calcium supple-
mented subjects with impaired fasting glucose, compared
to those receiving calcium only, but subjects were not vita-
min D deficient. Meanwhile, Taylor [15] reported an
increase in insulin resistance in 3 diabetic patients follow-
ing a single intramuscular dose of 300,000 IU of
25(OH)D2.
The importance of vitamin D in the maintenance of the
calcium economy and bone health is well known. A sig-
nificant positive correlation has been found between
serum vitamin D levels and bone mineral density in South
Asians living in India [16], Britain [17] and Bangladesh
[18]. An inverse relationship has been identified between
vitamin D status and OC, a marker of bone turnover [19].
Bone markers are useful for identifying changes in bone
metabolism, particularly when monitoring intervention
or therapy [20].
The population of interest in this study is women of South
Asian origin living in Auckland, New Zealand. There is a
high incidence of type 2 diabetes in South Asians living in
New Zealand; self-reported diabetes is over three times
higher for this group compared to national incidence
[21]. The possibility of an ethnic or genetic predisposition
to develop diabetes in this population is supported by epi-
demiological evidence from around the world [22] and
India itself where there are over 33 million people diag-
nosed with diabetes [23].
Between 1991 and 2001 the numbers of Asian Indians liv-
ing in New Zealand doubled. This trend has continued
exponentially with a current population of over 113,000
South Asians living predominantly in the Auckland area
[24]. The projections for future growth indicate that the
Asian population of which Indians are the second largest
group will increase from 272,000 in 2001 to 667,000 by
2021, an increase of 395,000 (145%) [24].
Very little is known about vitamin D status of this popu-
lation. However, a number of studies suggest that South
Asian migrants may have a higher risk of disease states
associated with low vitamin D status such as infantile rick-
ets, osteoporosis and both type-1 and type-2 diabetes
[22,25,26]. Reasons for low vitamin D status are various
and mostly unconfirmed. They include low incidental
exposure to sunlight, deliberate avoidance of sunlight,
limited dietary intake of vitamin D (there is no routine
fortification of the New Zealand food supply with vitamin
D) and possibly genetic factors. Polymorphisms in the
vitamin D receptor, which are thought to modify suscep-
tibility to diabetes, have been identified in both Indian
and Bangladeshi populations [27].
Hypotheses
• There is a high prevalence of hypovitaminosis D in
South Asian women living in Auckland, New Zealand.
￿ Supplementation of vitamin D in subjects who have
demonstrated insulin resistance and vitamin D deficiency
will result in an improvement in markers for metabolic
syndrome.
￿ Supplementation of vitamin D in subjects who have
demonstrated vitamin D deficiency will result in an
improvement in bone marker ratios in favour of bone
mineralisation.
Aims
￿ To establish the vitamin D status of South Asian women
living in Auckland, NZ.
￿ To investigate the effectiveness of vitamin D supplemen-
tation in improving insulin sensitivity in women with
hypovitaminosis D who have demonstrated insulin resist-
ance, and/or lipid profiles in those with dyslipidaemia.
￿ To investigate the effect of vitamin D supplementation
on bone marker ratios in women who have hypovitami-
nosis D.
Method
The study consists of two phases: Phase one included ini-
tial recruitment and screening, phase two included
recruitment of selected individuals into the vitamin D
intervention trial (Figure 1).BMC Public Health 2008, 8:267 http://www.biomedcentral.com/1471-2458/8/267
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Phase one provided the opportunity for a comprehensive
description of the population group with respect to gen-
eral health, anthropometry, diet and other lifestyle fac-
tors. The majority of the phase one data were collected
during one visit of the participant to either the Massey
Human Nutrition Research Unit or Mount Roskill Surgi-
cal and Medical Centre. Participants were weighed and
measured, blood samples taken, blood pressure and aural
temperature measured, then the participant was given
breakfast. During breakfast the medical history form was
completed and checked and the diet diary explained.
Participants
It was calculated that 42 subjects would be required for
each arm of the trial to demonstrate a significant differ-
ence at 80% power and 5% significance. Power calcula-
tions were based on the results of a lifestyle intervention
which achieved a reduction in HOMA-IR of 0.98 [28], and
derived from Margetts and Nelson [29].
Women were invited to participate in the study through
advertisements in suburban and Auckland newspapers,
and Indian media such as television, radio and newspa-
pers. Posters and leaflets were distributed in a number of
venues around Auckland such as General Medical Prac-
tices with high numbers of South Asian patients, clubs,
and temples. A number of South Asian social and commu-
nity groups were given presentations about the study by
the researchers.
A short television documentary on a channel popular
with Indian viewers elicited the greatest response of all the
methods used. However, the most effective form of pro-
motion was word-of-mouth. A relatively small group of
supportive women from the South Asian community pro-
moted the study and were instrumental in the successful
recruitment of 250 women.
Study design of the SURYA Study Figure 1
Study design of the SURYA Study.
End: Vitamin D, HOMA-IR, lipids, bone markers  
Baseline: Vitamin D, HOMA-IR, lipids, bone markers
Study population 
South Asian Women aged 20 
plus years 
Screen 250 women for 
vitamin D deficiency and 
insulin resistance
Identify 100 volunteers 
(assuming prevalence of 
±35%).  
4 capsules per day of 
cholecalciferol (4000IU) N=50 
6 months 
4 capsules per day of placebo 
N=50
6 months 
Stratified randomization
Phase 1: Commenced February 
2007, completed October 2007 
 Blood analysis 
 Anthropometry and clinical 
measurements 
 Medical history, dietary intake 
and questionnaires 
Phase 2: 
InterventionBMC Public Health 2008, 8:267 http://www.biomedcentral.com/1471-2458/8/267
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Inclusion/exclusion criteria
Women had to be 20+ years and of South Asian origin;
either the subject, both parents or all grandparents must
have been born on the Indian sub-continent i.e India,
Pakistan, Bangladesh, Sri Lanka – generally referred to as
South Asia.
Volunteers were excluded if suffering from significant
renal dysfunction, major systemic illness, or diabetes
requiring medication. Use of 25(OH)D3  supplements
exceeding 1000 IU/day (i.e. prescription dose), or any
form of calcitriol (1, 25(OH)2D3) were also exclusion cri-
teria.
Additional inclusion criteria for the intervention trial were
low vitamin D (<50 nmol/L) and a HOMA-IR (insulin
resistance) measurement of >1.93 or hyperinsulinaemia
(FPI >13 mIU/L) or hyperglycaemia (FPG 5.6 – 7.2 mmol/
L) or a triglyceride/HDL-C ratio >3.0. HOMA-IR >1.93
was based on the upper quartile determined in the Chen-
nai Urban Population Study-7 [30]. A triglyceride/HDL
ratio >3.0 has been shown to be a surrogate marker for
early insulin resistance in overweight/obese people [31].
Funding and ethics
Funding for the study was provided by the New Zealand
Lottery Board (Lottery Health Grant), New Zealand
Department of Internal Affairs. Additional support was
provided by Blackmores Pty Ltd, Australia, who supplied
the active supplement and the placebo.
Ethical approval was granted by the Massey University
Human Ethics Committee (Southern A), Reference No.
06/67 and the subjects signed an informed consent form
for participation in the study.
Setting
The study took place in Auckland, New Zealand. Auck-
land is New Zealand's largest city with a population of just
over 1 million. The majority of South Asian immigrants
settle in Auckland [24].
Vitamin D intervention
Initial screening (phase 1 of the study) took place over a
period of 9 months, commencing February 2007. See
Table 1 for outcome measures and testing methods for
phase 1. From the 250 women screened in phase 1, 116
qualified for phase 2, with the inclusion criteria described
above. Women with FPG >7.2 mmol/L were offered a sec-
ond blood test, and then withdrawn from the study and
referred to their medical practitioner if the second blood
test yielded similar results.
One hundred and six women were recruited for phase 2,
but a number were lost to the study due to becoming preg-
nant (n = 3), moving overseas (n = 6) perceived side-
Table 1: Outcome measures and testing methods used for phase one.
Measure Method
Blood analysis All analysed by LabPlus, Auckland City Hospital, Auckland
Fasting plasma insulin Micro-particle enzyme immunoassay technology (MEIA), Abbott Diagnostics
Fasting plasma glucose An enzymatic colourimetric assay; Roche Glucose reagent kit (Cat. No. 1876899)
Total cholesterol Enzymatic colourimetric method 
(Roeschlau and Allain). Roche Cholesterol reagent kit (Cat. No. 1491458)
Triglycerides Enzymatic conversion. Roche Triglycerides reagent kit (Cat. No. 1727711)
HDL-C Homogenous enzymatic colourimetric assay. Roche HDL-Cholesterol Plus reagent kit 
(Cat. No. 04713214)
LDL-C Calculated
Serum calcium Colourimetric assay. Roche Calcium reagent kit (Cat. No. 1730240)
Serum albumin Colourimetric assay. Roche Albumin Plus reagent kit (Cat. No. 1970909)
Serum high sensitivity CRP Particle enhanced immunoturbidimetric assay. Roche CRPLX reagent kit (Cat. No. 03002039)
Serum parathyroid hormone "ECLIA" electrochemiluminescence immunoassay. PTH Reagent Pack (Cat. No. 11972103122)
Serum 25 OH vitamin D Radioimmunoassay, DiaSorin RIA kit (Cat. No. 68100E)
Anthropmetric and clinical assessments:
Blood pressure Omron HEM-907 Digital Automatic Blood Pressure Monitor
Temperature Braun ThermoScan Pro 3000 aural thermometer
Height, weight, waist and hip circumference ISAK anthropometry methods – ISAK level one accredited anthropometrist, Tanita electronic 
scales, stadiometer, Lufkin tape
Questionnaires:
Dietary assessment 4-day food diary. Completed by subjects. Analysed using Foodworks 2007 (Xyris Software). 
Additional recipes and food lists provided by Indian dietitian
Medical and family history Questionnaire administered following blood tests
DemographicsBMC Public Health 2008, 8:267 http://www.biomedcentral.com/1471-2458/8/267
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effects (n = 2), medical practitioner prescribing vitamin D
(n = 3), or withdrew from study (n = 8).
The intervention consisted of a 25(OH)D3 supplement,
4000 international units (IU) per day, or placebo, in the
form of 4 oral capsules, for 6 months. The consumption
of 4000 IU 25(OH)D3 has been shown to be a safe and
effective dose [32,33]. The active supplement was tested
for 25(OH)D3 content by the Massey University Nutrition
laboratory. The average content per dose was 4226 IU, no
vitamin D was detected in the placebo. The vitamin D
content will be tested again at the completion of the study
to determine any degradation during storage over the
period of the study.
Subjects were matched into pairs by age and BMI. Ran-
domisation of the active/placebo capsules and allocation
to pairs was performed by Blackmores using nQuery Advi-
sor®, version 6.0, (Statistical Solutions, Cork, Ireland).
Randomisation and allocation were fully concealed from
the researchers.
Once recruited into phase two, participants were recalled
for a baseline blood test prior to being given their supply
of supplements. After 3 months another blood sample
was taken to check for hypercalcaemia. Once the interven-
tion was completed (6 months) participants provided one
more blood sample and were weighed again. See Table 2
for outcome measures and testing methods for the inter-
vention phase of the study.
Blood sampling and processing
Venous blood samples were taken by registered phleboto-
mists, using a sterile Vacutainer Flashback needle and nee-
dle holder between 8.30 am and 9.30 am. There is
considerable circadian variability in bone markers; OC
levels are increased by 20% at peak (very early morning)
and CTX levels at the nadir may be half those at the noc-
turnal peak [20]. Accordingly, all blood samples were
obtained within a consistent time period. The subjects
were asked to fast overnight (at least 8 hours with no food
or beverage, excluding water). Serum was used for the
analysis of lipid profiles, CRP, calcium, albumin, parath-
yroid hormone, glucose, insulin, vitamin D. The blood
was protected from light, allowed to clot for ± 30 minutes
and centrifuged for 10 minutes at 2000 g at 4°C within 2
hours. For the preparation of plasma, the blood was col-
lected in vacutainers buffered with EDTA anticoagulant,
and centrifuged for 10 minutes at 2000 g at 4°C. For OC
and CTX, plasma was dispensed and frozen within 2
hours of collection and flown to Christchurch, New Zea-
land on dry ice for analysis at conclusion of the study.
Aliquots of serum and plasma were stored at -80°C whilst
awaiting analysis.
Questionnaires
The medical history form was completed by participants
during their visit for blood tests and anthropometry.
Before the participant departed the researcher checked all
answers and probed any responses requiring clarification.
The questionnaire included basic demographics, country
of birth, length of time in New Zealand and number of
years of education since age 5 years. All medication and
dietary supplement use was recorded, together with
tobacco, betel nut and alcohol use, menstrual status, birth
control and/or HRT use, and dental history. Family his-
tory of diabetes, CVD and osteoporosis was also investi-
gated.
The 4-day estimated dietary record was presented in an
open entry booklet form with pages for recording each
day's food intake and extra pages for recipes. Participants
were asked to record at least one weekend or feast day.
Measuring cups and spoons were provided if required.
Instructions for the completion of the diary were given
verbally when the participant received the diary and a list
of written instructions, including examples, were pro-
vided on the first 2 pages of the booklet. The women were
asked to give a detailed description of the foods eaten, if
possible to give a brand name and to estimate the
amounts using natural measures (e.g., pieces, slices) or
household measures (e.g., coffee spoon, cup). Experi-
enced dietitians used a standardised protocol, including a
manual on household weights and measures to convert
the estimated amounts into weights. All dietary records
were checked for quality and completeness prior to data
entry into the Foodworks 2007 programme. Additional
new foods and recipes were added as required, with food
composition data taken from an Indian food composition
reference [34]. The recipes were adapted for individual
Table 2: Outcome measures and testing method for phase two (measured at baseline, 3 months and 6 months)
Test Method
Blood tests
As listed in table 1, plus:
Collagen C-telopeptide (CTX)
Osteocalcin (OC)
Roche Elecsys beta cross-laps
Roche Elecsys 2010
Canterbury District Health Board Laboratory
Weight at baseline and 6 months Tanita electronic scalesBMC Public Health 2008, 8:267 http://www.biomedcentral.com/1471-2458/8/267
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subjects based on the ingredients that are being used in
New Zealand. After data entry, each record was verified by
a nutrition researcher and corrections were made if mis-
interpretation or errors in data entry were found. To
ensure the best possible quality of dietary data, a subset of
subjects were recalled for a qualitative, in-depth interview
with a dietitian assessing their 4-day food records for die-
tary content (quality and quantity), food types, additions
to foods and drinks and recipe composition (to further
clarify fat and sugar intake.)
In the present study, a 4-day estimated dietary record was
chosen because of the high respondent burden and time-
consuming characteristics of 7-day dietary food records.
However, Nelson et al [35] stated that a 4-day record, ran-
domised to cover weekday variations, seems to be the
optimum. To obtain a highly accurate estimate of individ-
ual intake, a longer period would be recommended for
many nutrients, especially those with a high within-per-
son variation, but this was not feasible due to practical
considerations [36].
Participants were given a free-post, pre-addressed enve-
lope for the return of the booklet.
Provision of results to participants
Following the receipt and analysis of the 4-day diet diary
and the completion of the biochemical assays done dur-
ing the screening phase, each participant received a feed-
back form. This contained an overview of the analysis of
the diet, with particular reference to macronutrients, iron
and calcium. Anthropometric measurements, blood pres-
sure and blood results (fasting glucose, fasting insulin and
lipids) were also included. Once recruitment into the trial
was completed, participants not involved in the trial
received notification of their vitamin D levels together
with advice about supplementation where applicable.
On completion of the trial, participants will be informed
of their current vitamin D status, their baseline status and
if they were taking the active or placebo dose. All trial par-
ticipants will be given 6 months supply of vitamin D sup-
plements (courtesy of Blackmores), regardless of which
arm of the trial they were on, upon completion of the 6-
month intervention.
Newsletters were sent to all participants at intervals during
the study with the goal of keeping them interested and
informed.
Data Handling and statistical analysis
Name and address details were maintained in Microsoft
Access. Check boxes recorded the progress of a participant
through the study and thus allowed personalised letters to
be sent to groups of participants as required throughout
the study. All other data were entered into a single Micro-
soft Excel spreadsheet with participants identified only by
their unique Subject Number. All entries were double-
checked by another member of the research team.
Before commencement of statistical analysis the data will
be cleaned and checked for coding errors. Descriptive sta-
tistics will be used for the baseline population characteris-
tics: mean (SD), median, mode and range summary
statistics, independent t-tests and paired t-tests for numer-
ical normally distributed data, and Mann Whitney U and
Wilcoxon Paired Rank Test (for paranormal distribution)
and Chi-Squared tests (for categorical data). Spearman
(checked with Pearson) correlations and ANOVA will be
calculated to test for associations between variables.
The primary analysis will be a comparison of the change
of the primary outcome (vitamin D status) between the
intervention and the control group following the 'inten-
tion to treat' principle at three months and six months. In
order to assess whether protocol deviations have caused
bias, the results of the intention-to-treat analyses will be
compared to 'per protocol' analyses. Furthermore second-
ary analyses will be performed to explore intervention
effects on the insulin resistance, HDL/triglycerides and
bone markers. Analysis of covariance will be used to ana-
lyse the effects of treatment on changes in variables while
controlling for the effects of possible confounding factors
for example different baseline conditions (e.g. BMI). Sta-
tistical analyses will be performed by using SPSS software
(version 15).
Discussion
The information that was obtained from the screening
phase of this study provided a valuable and unique
insight into this rapidly increasing group of migrants
entering New Zealand. It was not the intention during this
phase to conduct a cross-sectional study and there was no
attempt to recruit in a fully randomised way. Indeed, such
recruitment in any specific, ethnic minority within a large
population would be highly problematic. However, the
250 women who participated in phase one of the Surya
Study represent approximately 0.5% of the total number
of South Asian women living in New Zealand. Distribu-
tion in terms of country of origin reflected that of the
entire population as reported in the 2006 census [24].
Level of education, although higher than the New Zealand
national average, was as expected of a newly migrant pop-
ulation given New Zealand's immigration requirements
for high educational standards [37].
As far as we are aware, there has been no other ran-
domised, placebo-controlled, double-blind trial investi-
gating the effect of vitamin D supplementation on insulin
resistance and other markers of metabolic syndrome. IfBMC Public Health 2008, 8:267 http://www.biomedcentral.com/1471-2458/8/267
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this trial is successful, it will provide another clue about
the aetiology of type 2 diabetes, and the opportunity to
reduce one of the many risk factors.
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